These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9394998)

  • 21. Mucha-Habermann disease-like eruptions due to Tegafur.
    Kawamura K; Tsuji T; Kuwabara Y
    J Dermatol; 1999 Mar; 26(3):164-7. PubMed ID: 10209923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knuckle pad-like keratoderma: a new cutaneous side reaction induced by tegafur.
    Won YH; Seo JJ; Kim SJ; Lee SC; Chun IK
    Int J Dermatol; 1998 Apr; 37(4):315-7. PubMed ID: 9585908
    [No Abstract]   [Full Text] [Related]  

  • 23. Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative.
    Ohara S; Hayashi R; Hata S; Itoh N; Hanyu N; Yamamoto K
    Acta Neuropathol; 1998 Nov; 96(5):527-31. PubMed ID: 9829818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral tegafur/uracil.
    Wellington K; Goa KL
    Drugs Aging; 2001; 18(12):935-48; discussion 949-50. PubMed ID: 11888348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of drug-induced pulmonary injury showing organizing pneumonia pattern due to S-1].
    Nakata H; Shinano H; Kuraya D; Fujioka Y
    Gan To Kagaku Ryoho; 2012 Jun; 39(6):955-7. PubMed ID: 22705691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Side effects analyses in consideration of renal function for S-1-administered patients].
    Iwai M; Kimura M; Yoshimura T; Yasuda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):973-6. PubMed ID: 21677489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of Ophthalmic Disorders in Patients Treated with the Antineoplastic Agent S-1.
    Moriya K; Shimizu H; Handa S; Sasaki T; Sasaki Y; Takahashi H; Nakamura S; Yoshida H; Kato Y
    Gan To Kagaku Ryoho; 2017 Jun; 44(6):501-506. PubMed ID: 28698442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
    Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
    Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
    Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
    Maeda M; Saito Y; Makino Y; Iwase H; Hayashi Y
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):79-83. PubMed ID: 26809530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
    Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
    Rios-Buceta L; Buezo GF; Peñas PF; Dauden E; Fernandez-Herrera J; Garcia-Diez A
    Acta Derm Venereol; 1997 Jan; 77(1):80-1. PubMed ID: 9059693
    [No Abstract]   [Full Text] [Related]  

  • 33. [A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer].
    Kashima Y; Adachi T; Hara N; Sohtome I; Shirasaka T
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):469-72. PubMed ID: 22421782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
    Deenen MJ; Terpstra WE; Cats A; Boot H; Schellens JH
    Ann Intern Med; 2010 Dec; 153(11):767-8. PubMed ID: 21135311
    [No Abstract]   [Full Text] [Related]  

  • 35. Effective chemoradiotherapy without additive toxicity in locoregionally advanced head and neck cancer.
    Nagy B; Molnar J; Rovo L; Paczona R; Thurzo L
    Anticancer Res; 2003; 23(5b):4329-32. PubMed ID: 14666647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S-1 induces meibomian gland dysfunction.
    Matsumoto Y; Dogru M; Sato EA; Ibrahim OM; Tatematsu Y; Ogawa Y; Tsubota K
    Ophthalmology; 2010 Jun; 117(6):1275.e4-7. PubMed ID: 20522337
    [No Abstract]   [Full Text] [Related]  

  • 37. [Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
    Fujii C; Kimura Y; Makari Y; Mikami J; Fujita J; Kamigaki S; Hayashi H; Yanagishita Y; Yasui Y; Ishizaka T
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1960-1962. PubMed ID: 28133189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
    Esmaeli B; Golio D; Lubecki L; Ajani J
    Am J Ophthalmol; 2005 Aug; 140(2):325-7. PubMed ID: 16086962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tegafur chemotherapy for the treatment of gut and liver cancer.
    Piccinini L; Corradini R; Vandelli C; Luppi G; Di Marco G
    Int J Clin Pharmacol Res; 1986; 6(3):255-60. PubMed ID: 3091513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
    Sawaki A; Mizuno N; Hoki N; Ishikawa H; Takagi T; Yamao K
    Gan To Kagaku Ryoho; 2007 Dec; 34(13):2301-3. PubMed ID: 18079635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.